The non-alcoholic steatohepatitis (NASH) treatment market is anticipated to experience considerable growth by 2032, according to a new report by DelveInsight. This growth is attributed to the introduction of emerging therapies and a deeper understanding of the disease. The report provides insights into the NASH market across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Emerging Therapies and Market Dynamics
Several pharmaceutical companies are actively involved in developing novel therapies for NASH. These include:
- Inventiva Pharma
- Zydus Therapeutics
- Novo Nordisk A/S
- Eli Lilly and Company
- Madrigal Pharmaceuticals
- Terns, Inc.
- Intercept Pharmaceuticals
- Enyo Pharma
- 89bio, Inc.
- Akero Therapeutics
These companies are focusing on different therapeutic candidates in Phase II and Phase III stages, aiming to address the unmet needs in NASH treatment. Key therapies expected to launch in the market include TERN-101, SNP-610, LJN452 (tropifexor + licogliflozin), PXL065, and Efruxifermin (EFX), among others.
NASH Epidemiology and Market Trends
NASH is characterized by liver inflammation and damage caused by fat accumulation. The disease often presents without noticeable symptoms, making early diagnosis challenging. As NASH progresses, patients may experience fatigue, weight loss, and abdominal discomfort. The report highlights that the NASH market is expected to witness major changes between 2019 and 2032.
The increasing prevalence of NASH, driven by factors such as obesity and diabetes, is a significant driver for market growth. The report provides detailed insights into the historical and current NASH patient pool, as well as forecasted trends across the seven major markets.
Key Market Players and Therapeutic Approaches
Major companies such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are at the forefront of developing targeted therapeutics for NASH. These companies are exploring various approaches, including:
- Thyroid receptor-beta (THR-β) agonists
- Farnesoid X receptor (FXR) agonists
- Glucagon-like peptide-1 (GLP-1) receptor agonists
The development of these novel therapies is expected to significantly impact the NASH treatment landscape, offering new options for patients and driving market growth.
